Sequential cytogenetic study of patients after bone marrow transplantation

Zemanová, Zuzana; Michalová, K; Musilová, Jana; Lukásová, M; Starý, Jan

doi:10.1016/0165-4608(94)90113-9

Cited by 5 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, our results suggest that the disappearance of the original abnormal clone is associated with the induction of clinical remission and that the reappearance of an abnormal karyotype is prognostically unfavorable. 12,24,25 Regarding the prognostic value of the presence of host cells, it was found, as in previous studies, 9,10 that the progressive increase of host cells is related to clinical and hematological relapse, whereas patients who developed a tMC remain in clinical remission. Our results are in contrast to those of Bourhis et al, 26 who showed that patients with у5% host cells had a higher probability of relapse.…”

Section: Discussionmentioning

confidence: 49%

“…[6][7][8] Different methods have been applied for detecting chimerism: cytogenetics, restriction fragment length polymorphism (RFLP), fluorescence in situ hybridization (FISH) and PCR techniques. [9][10][11][12][13][14][15][16][17][18][19] Differing conclusions have emerged concerning the value of mixed chimerism (MC) for detecting impending relapse. While in severe aplastic anemia (SAA) or chronic myeloid leukemia (CML) the risk of relapse or graft failure were related to an increase of the frequency of host cells, the prognostic value for predicting relapse in patients with acute leukemias remains controversial.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Follow-up of chimerism in children with hematological diseases after allogeneic hematopoietic progenitor cell transplants

Ortega

Escudero

Caballín

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Using in situ hybridization with an X and Y chromosome probe mixture, 106 bone marrow samples from 38 patients with malignant and non-malignant hematological diseases who received sex-mismatched allogeneic hematopoietic progenitor cell transplants (PCT) in a single institution within short-term intervals (1, 3, 6, 12, 24 and Ͼ24 months) have been sequentially studied. The patients received either HLA-identical (n = 31) or nonidentical (n = 7) PCT. Twenty-six children showed donor chimerism, 10 children showed mixed chimerism (MC) and two children presented autologous reconstitution. Chimerism status with different parameters has been related (age, sex, donor, disease status before PCT, conditioning regimen, GVHD prophylaxis, relapse, GVHD and survival). Our results indicate that female patients (P = 0.011) and a less intensive conditioning regimen (P = 0.039) are significantly associated with the MC status. Mixed chimerism is not, per se, significantly associated with leukemia relapse but an increase of the MC is indicative of clinical relapse. Keywords: FISH; mixed chimerism; minimal residual disease; conditioning regimen; relapse Allogeneic hematopoietic progenitor cell transplants (PCT) are considered to be advantageous in particular malignant hematological diseases. 1-3 The success of this treatment modality is mainly affected by relapse or graft rejection. For patients receiving unmodified marrow transplants for leukemias in early stages, relapse rates range from Ͻ10% to 40%, depending on patient selection, treatment regimen, and the length of follow-up. Patients with more advanced states of leukemia have a higher relapse rate, approaching 50% to 70%, with T cell depletion (TCD) and absence of graft-versus-host disease (GVHD) being important prognostic factors for relapse. 4 Other factors responsible for relapse and/or graft rejection may be insufficient conditioning regimens or a deficient graft-versus-leukemia (GVL)

show abstract

Section: Discussionmentioning

confidence: 49%

mentioning

confidence: 99%

Follow-up of chimerism in children with hematological diseases after allogeneic hematopoietic progenitor cell transplants

Ortega

Escudero

Caballín

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…EDITOR—Bone marrow transplantation is used in several haematological diseases, such as acute and chronic leukaemia, aplastic anaemia, and severe congenital immunodeficiencies 1. The survival rate has improved greatly over the past decade 2.…”

mentioning

confidence: 99%

“…It is, however, well known to haematologists who use cytogenetic examination for monitoring the period after transplantation in patients with chronic myeloid leukaemia or in those who received bone marrow cells from a patient of opposite sex. 1 3…”

mentioning

confidence: 99%